Welcome to our dedicated page for Macrogenics news (Ticker: MGNX), a resource for investors and traders seeking the latest updates and insights on Macrogenics stock.
MacroGenics, Inc. develops antibody-based therapeutics for cancer, with pipeline work built around monoclonal antibodies, DART and TRIDENT multi-specific molecules, and antibody-drug conjugates. Company news commonly covers clinical and regulatory updates for lorigerlimab, MGC026 and MGC028, including FDA communications tied to study conduct and safety monitoring.
Updates also address financial results, capital-resource commentary, strategic collaborations and licensing economics, including royalty interests tied to ZYNYZ (retifanlimab-dlwr), a PD-1 inhibitor originally developed by MacroGenics and licensed to Incyte.
MacroGenics (NASDAQ: MGNX) reported that Gilead Sciences has exercised its option to obtain an exclusive license to a preclinical bispecific program under their 2022 collaboration, triggering a $10 million payment to MacroGenics.
The licensed solid-tumor program uses MacroGenics’ TRIDENT® platform and targets two undisclosed antigens. According to MacroGenics, the collaboration covers three programs in total: MGD024, a clinical-stage CD123 × CD3 DART® molecule, plus two preclinical bispecific programs. MacroGenics remains eligible to receive up to approximately $1.6 billion in additional development, regulatory and commercial milestone payments across the collaboration, as well as royalties on potential worldwide net sales from resulting products.
MacroGenics (NASDAQ: MGNX) provided a clinical update on its ongoing Phase 1, first-in-human study of MGC026, a B7-H3–directed antibody-drug conjugate with a topoisomerase I inhibitor payload, in patients with advanced solid tumors. Dose escalation from 1 to 9 mg/kg every three weeks has been completed, and a 7.5 mg/kg q3W dose is being evaluated in four tumor-specific cohorts: recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN), endometrial cancer, melanoma and soft tissue sarcoma.
The SCCHN cohort, using Simon’s two-stage design with a planned 40 patients, achieved its pre-specified Stage 1 response threshold and has moved to Stage 2 enrollment. As of July 8, 2026, 74 patients had been enrolled across dose escalation and cohort expansion. According to MacroGenics, no cases of interstitial lung disease or ocular toxicity had been reported by that date, and evidence of anti-tumor activity had been observed across several indications. Detailed dose escalation and preliminary cohort data will be presented in a poster at the ESMO 2026 Congress in Madrid from October 23-27, alongside a separate Phase 2 poster on lorigerlimab in advanced gynecologic cancers.
MacroGenics (NASDAQ: MGNX) completed the sale of its GMP drug substance manufacturing operations to Bora Pharmaceuticals on July 2, 2026. Bora paid $122.5 million, before fees and adjustments, and assumed responsibility for clinical and commercial manufacturing.
The Rockville manufacturing site, Frederick warehouse, and about 140 employees transferred to Bora. MacroGenics also signed a supply agreement under which Bora will provide process development and drug substance production for MacroGenics’ internal pipeline.
MacroGenics (NASDAQ: MGNX) will receive a $24.5 million regulatory milestone payment from Sanofi following FDA accelerated approval of TZIELD (teplizumab-mzwv) to delay decline in endogenous insulin production in children aged 8–17 with stage 3 type 1 diabetes.
MacroGenics remains eligible for up to $305 million in additional milestones and retains a single-digit royalty on global net sales above a specified annual threshold.
MacroGenics (Nasdaq: MGNX) announced that President and CEO Eric Risser will participate in a fireside chat at the Stifel 2026 Virtual Targeted Oncology Forum on May 20, 2026, at 10:30 a.m. ET.
A live webcast and 30-day replay will be available in the Investor Relations section of MacroGenics' website.
MacroGenics (NASDAQ: MGNX) reported Q1 2026 revenue of $20.8 million, up from $13.2 million, and a net loss of $36.8 million versus $41.0 million a year earlier.
The company agreed to sell its manufacturing operations to Bora for $122.5 million and expanded ZYNYZ royalty monetization for $60 million plus up to $20 million, extending its projected cash runway through 2028. ADC programs MGC026, MGC028 and preclinical MGC030 remain on track for 2026–2027 milestones, while lorigerlimab showed a 25% objective response rate in clear cell gynecologic cancer but will no longer be pursued in platinum-resistant ovarian cancer.
MacroGenics (NASDAQ: MGNX) agreed to sell its GMP drug substance manufacturing operations to Bora Pharmaceuticals for an upfront payment of $122.5 million, before fees. The deal includes MacroGenics’ Rockville FDA-approved 11,000-liter facility, Frederick warehouse, CDMO operations and about 140 employees, with closing expected in Q3 2026.
Upon closing, Bora will assume clinical and commercial manufacturing, while MacroGenics retains pipeline support through a supply arrangement with Bora.
MacroGenics (Nasdaq: MGNX) entered an expanded royalty purchase agreement with Sagard Healthcare Partners to sell a capped royalty interest in ZYNYZ (retifanlimab-dlwr).
MacroGenics will receive a $60 million upfront payment and may receive an additional 2026 sales-based milestone up to $20 million. Royalties revert when Sagard receives 1.7x its investment by Sept 30, 2032 or 2.0x thereafter. MacroGenics retains other economic interests, including development, regulatory, and commercial milestones.
MacroGenics (NASDAQ: MGNX) announced the FDA has removed a partial clinical hold on its Phase 2 LINNET study of lorigerlimab, a bispecific DART molecule targeting PD-1 and CTLA-4.
The company plans to resume enrollment under a revised protocol with additional risk-mitigation measures for hematologic and cardiac toxicities and remains on track to provide a mid-2026 clinical update.
MacroGenics (NASDAQ: MGNX) reported 2025 results, operational updates and 2026 data timelines. Key milestones include initial Phase 1 data for MGC026 in mid-2026, initial Phase 1 data for MGC028 in H2 2026, and an IND submission for MGC030 targeted for 3Q 2026. Cash, cash equivalents and marketable securities were $189.9M as of December 31, 2025, with a stated cash runway into late 2027. 2025 revenue totaled $149.5M, R&D expense was $147.2M, and net loss was $74.6M. The company noted partnership milestone upside with Gilead, Sanofi and Incyte.